Pfizer biosimilar matches Herceptin in Phase III trial

Pfizer Inc. (NYSE:PFE) said its biosimilar candidate PF-05280014 showed equivalence to reference product Herceptin trastuzumab, meeting the primary endpoint in the Phase III REFLECTIONS B3271002 trial to treat HER2-positive metastatic breast cancer. Pfizer spokesperson Rachel Hooper declined to disclose the company’s regulatory submission plans.

The 690-patient trial's primary endpoint compared objective response rates (ORRs) for PF-05280014 plus paclitaxel vs. Herceptin plus paclitaxel...